In plain language
In 252 percutaneous coronary interventions (PCIs) performed by one interventional cardiologist, measured operator dose per procedure was about 17% higher with right radial access than with femoral access. Operator and patient doses tracked closely.
At a glance
- Type of study
- Original research, Prospective cohort study
- Who was studied
- Interventional cardiologists, Patients
- Size
- n = 252 procedures
- Summary based on
- the abstract
What it found
Operator radiation exposure was significantly higher with right radial access than with femoral access during PCI.
Key figures: 40.5 ± 20.2 µSv femoral vs 47.5 ± 26.5 µSv radial (p < 0.02)
Physician and patient radiation exposure levels were strongly correlated.
Patient body mass index was not correlated with radiation exposure levels.
Limits to keep in mind
Single operator at a single hospital with a single-plane unit, so results may not generalize; observational, non-randomized access-site choice, and only an abstract was available.
Related research summaries
- Radiation exposure in interventional cardiology: Implications for patients and healthcare workers (2026, Dosimetry measurement study)
- Two Central Nervous System Tumors in One Catheter Lab: Time to Rethink Radiation Protection (2026, Retrospective cohort study)
- Dosimetry During Percutaneous Coronary Interventions Of Chronic Total Occlusions (2018, Dosimetry measurement study)
- Factors Contributing To Radiation Dose For Patients And Operators During Diagnostic Cardiac Angiography (2018, Retrospective cohort study)
- Operator radiation exposure during transradial coronary angiography: Effect of single vs. double catheters (2017, Randomized trial)
How this summary was made
ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.
Prepared November 3, 2026.